Vincerx Pharma Inc (VINC) concluded trading on Wednesday at a closing price of $0.11, with 8.6 million shares of worth about $0.95 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -82.99% during that period and on January 22, 2025 the price saw a loss of about -24.47%. Currently the company’s common shares owned by public are about 31.40M shares, out of which, 28.49M shares are available for trading.
Stock saw a price change of -34.74% in past 5 days and over the past one month there was a price change of -48.64%. Year-to-date (YTD), VINC shares are showing a performance of -57.61% which decreased to -89.59% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.14 but also hit the highest price of $9.37 during that period. The average intraday trading volume for Vincerx Pharma Inc shares is 7.33 million. The stock is currently trading -42.56% below its 20-day simple moving average (SMA20), while that difference is down -51.82% for SMA50 and it goes to -81.67% lower than SMA200.
Vincerx Pharma Inc (NASDAQ: VINC) currently have 31.40M outstanding shares and institutions hold larger chunk of about 30.24% of that.
The stock has a current market capitalization of $4.06M and its 3Y-monthly beta is at 1.13. It has posted earnings per share of -$1.03 in the same period. It has Quick Ratio of 2.17 while making debt-to-equity ratio of 0.18. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for VINC, volatility over the week remained 16.21% while standing at 18.47% over the month.
Analysts are in expectations that Vincerx Pharma Inc (VINC) stock would likely to be making an EPS of 0 in the current quarter, while forecast for next quarter EPS is 0 and it is 0 for next year. For the current quarter EPS, analysts have given the company a lowest target 0 which is 0 at the higher side of the target for the same. Stock’s fiscal year EPS is expected to rise by 59.79% while it is estimated to increase by 39.47% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by H.C. Wainwright on January 14, 2022 offering a Buy rating for the stock and assigned a target price of $25 to it. Coverage by Cantor Fitzgerald stated Vincerx Pharma Inc (VINC) stock as an Overweight in their note to investors on December 23, 2021, suggesting a price target of $25 for the stock. On November 01, 2021, SVB Leerink Initiated their recommendations, while on September 13, 2021, Laidlaw Initiated their ratings for the stock with a price target of $30. Stock get a Buy rating from B. Riley Securities on August 25, 2021.
